These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29757301)

  • 41. The Vulvodynia Experience Questionnaire: Qualitative Development of a New Patient-Reported Outcome Measure for Vulvodynia.
    Goldstein AT; Diez PMQ; Kapanadze S; Cala ML; Evans CJ; Whyte JL; Christoph A
    J Sex Med; 2020 Oct; 17(10):2055-2066. PubMed ID: 32900670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis.
    Pariser D; Schenkel B; Carter C; Farahi K; Brown TM; Ellis CN;
    J Dermatolog Treat; 2016; 27(1):19-26. PubMed ID: 26138406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qualitative exploration of the visual function impairments and impacts on vision-dependent activities of daily living in Retinitis Pigmentosa and Leber Congenital Amaurosis: content validation of the ViSIO-PRO and ViSIO-ObsRO measures.
    Kay C; Audo I; Naujoks C; Spera C; Fischer MD; Green J; Durham T; Williamson N; Bradley H; Barclay M; Sims J; Banhazi J; Patalano F
    J Patient Rep Outcomes; 2023 Jul; 7(1):74. PubMed ID: 37466759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
    McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
    Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN).
    Williams-Hall R; Berry P; Williamson N; Barclay M; Roberts A; Gater A; Tolley C; Bradley H; Ward A; Hsia E; Zuraw Q; DeLong P; Touma Z; Strand V
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 36007978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID).
    Hareendran A; Mannix S; Skalicky A; Bayliss M; Blumenfeld A; Buse DC; Desai PR; Ortmeier BG; Sapra S
    Health Qual Life Outcomes; 2017 Nov; 15(1):224. PubMed ID: 29149901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and content validity of a hemodialysis symptom patient-reported outcome measure.
    Flythe JE; Dorough A; Narendra JH; Wingard RL; Dalrymple LS; DeWalt DA
    Qual Life Res; 2019 Jan; 28(1):253-265. PubMed ID: 30229532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Content Validity of Sjögren's Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren's.
    Griffiths N; Wratten S; Flynn J; Bookman AAM; Ndife B; Hueber W; Goswami P
    Rheumatol Ther; 2022 Dec; 9(6):1559-1574. PubMed ID: 36152275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis.
    Gisondi P; Geat D; Bellinato F; Spiazzi L; Danese E; Montagnana M; Lippi G; Girolomoni G
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
    Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS
    Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: Qualitative Research.
    Gelhorn HL; Bodhani AR; Wahala LS; Sexton C; Landrian A; Miller MG; Derogatis L; Dobs A; Revicki DA
    J Sex Med; 2016 Nov; 13(11):1729-1736. PubMed ID: 27717790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
    Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
    Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling.
    Lewis-Beck C; Abouzaid S; Xie L; Baser O; Kim E
    Patient Prefer Adherence; 2013; 7():199-205. PubMed ID: 23508007
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.